Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor.

Melanomas respond poorly to chemotherapy. In this study, we investigated the sensitization of B16 mouse melanoma tumors to paclitaxel by a combination of two tyrosine kinase inhibitors: vatalanib, targeting vascular endothelial growth factor receptors, and imatinib, an inhibitor targeting for example, Abl/BCR-ABL, the platelet-derived growth factor receptor, and stem cell factor receptor c-Kit. C57Bl6/J mice carrying B16/PDGF-BB mouse melanoma tumors were treated daily with vatalanib (25 mg/kg), imatinib (100 mg/kg), or a combination of these drugs. Paclitaxel was given subcutaneously twice during the study. The effects of the drugs on tumor cell proliferation in vitro were determined by counting cells. B16/PDGF-BB mouse melanoma tumors were not sensitive to paclitaxel at doses of either 5 or 20 mg/kg. However, the tumor growth was significantly reduced by 58%, in response to paclitaxel (5 mg/kg) when administered with daily doses of both vatalanib and imatinib. Paclitaxel only inhibited the in-vitro growth of B16/PDGF-BB tumor cells when given in combination with imatinib. Imatinib presumably targets c-Kit, as the cells do not express platelet-derived growth factor receptor and as another c-Abl inhibitor was without effect. This was supported by data from three c-Kit-expressing human melanoma cell lines showing varying sensitization to paclitaxel by the kinase inhibitors. In addition, small interfering RNA knockdown of c-Kit sensitized the cells to paclitaxel. These data show that combination of two tyrosine kinase inhibitors, imatinib and vatalanib, increases the effects of paclitaxel on B16/PDGF-BB tumors, thus suggesting a novel strategy for the treatment of melanomas expressing c-Kit.
AuthorsAgnieszka Kłosowska-Wardęga, Yoko Hasumi, Aive Åhgren, Carl-Henrik Heldin, Carina Hellberg
JournalMelanoma research (Melanoma Res) Vol. 21 Issue 1 Pg. 57-65 (Feb 2011) ISSN: 1473-5636 [Electronic] England
PMID20975605 (Publication Type: Journal Article)
Chemical References
  • Angiogenesis Inhibitors
  • Benzamides
  • Phthalazines
  • Piperazines
  • Proto-Oncogene Proteins c-sis
  • Pyridines
  • Pyrimidines
  • RNA, Small Interfering
  • platelet-derived growth factor BB
  • vatalanib
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins c-kit
  • Paclitaxel
  • Angiogenesis Inhibitors (administration & dosage)
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Benzamides (administration & dosage)
  • Cell Line, Tumor
  • Cell Proliferation
  • Drug Synergism
  • Imatinib Mesylate
  • Melanoma, Experimental (drug therapy)
  • Mice
  • Mice, Inbred C57BL
  • Paclitaxel (administration & dosage)
  • Phthalazines (administration & dosage)
  • Piperazines (administration & dosage)
  • Protein-Tyrosine Kinases (antagonists & inhibitors)
  • Proto-Oncogene Proteins c-kit (metabolism)
  • Proto-Oncogene Proteins c-sis (metabolism)
  • Pyridines (administration & dosage)
  • Pyrimidines (administration & dosage)
  • RNA, Small Interfering (metabolism)
  • Signal Transduction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: